Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.
Zdenkowski N, Forbes JF, Boyle FM, Kannourakis G, Gill PG, Bayliss E, Saunders C, Della-Fiorentina S, Kling N, Campbell I, Mann GB, Coates AS, Gebski V, Davies L, Thornton R, Reaby L, Cuzick J, Green M; Australia and New Zealand Breast Cancer Trials Group.
Zdenkowski N, et al. Among authors: kling n.
Ann Oncol. 2016 May;27(5):806-12. doi: 10.1093/annonc/mdw055. Epub 2016 Feb 9.
Ann Oncol. 2016.
PMID: 26861603
Free article.
Clinical Trial.